EYLEA MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Eylea Market Size and Forecast – 2025 - 2032

The Global Eylea Market is estimated to be valued at USD 838.6 Mn in 2025 and is expected to reach USD 673.7 Mn by 2032, declining at a negative compound annual growth rate (CAGR) of -3.1% from 2025 to 2032. The market is experiencing a decrease due to factors such as the increasing competition from biosimilars, pricing pressures, and the availability of alternative treatments.

Key Takeaways of the Global Eylea Market

• In 2025, Neovascular (Wet) Age-Related Macular Degeneration (AMD) segment is estimated to dominate the global Eylea market, accounting for the largest share of 40. 2%.
• Based on dosage strength, the 2 mg segment is projected to hold the highest share at 45. 5% in 2025.
• The pre-filled syringe form segment is projected to lead the market, contributing 53.4% of the total share in 2025.
• North America is expected to lead the market, holding a share of 38. 3% in 2025.
• Asia Pacific is anticipated to be the fastest-growing region, with a market share of 24. 2% in 2025.

Market Overview

The Eylea market is experiencing a slight decline in growth due to various factors such as increasing competition from biosimilars, the emergence of alternative therapies, and potential patent expirations. However, the market is still expected to maintain a significant share due to Eylea's established efficacy in treating various ophthalmic conditions, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. The growing prevalence of these eye disorders, along with an aging population, will continue to drive the demand for Eylea, though at a slower pace compared to previous years.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Eylea Market Insights, By Indication - Neovascular (Wet) Age-Related Macular Degeneration (AMD) Dominates the Market Due to Rising Prevalence of Age-Related Macular Degeneration, Superior Efficacy & Safety, and Treatment Convenience

In terms of indication, the neovascular (wet) Age-related Macular Degeneration (AMD) segment is estimated to account for highest share of the market with 40.2% in 2025, owing to the increasing prevalence of AMD, particularly in the aging population. As the global population continues to age, the incidence of Age-related macular degeneration  is expected to rise, driving the demand for effective treatments like Eylea.

For instance, in September 2022, Age-related Macular Degeneration (AMD) was the leading cause of irreversible blindness in older adults, affecting 200 million people worldwide, with projections to reach 300 million by 2040. It primarily affects those over the age of 60, with higher prevalence in Caucasian populations, though it also impacts Asian and African American groups. The aging global population is driving an increase in AMD cases, which poses significant public health and economic challenges.

Furthermore, the superior efficacy and safety profile of Eylea in treating Neovascular AMD has been a major driving force behind its market dominance. Clinical studies have consistently demonstrated Eylea's ability to improve visual acuity and reduce the progression of the disease, making it a preferred choice among healthcare professionals and patients alike.

Eylea Market Insights, By Dosage Strength - 2 mg Dosage Strength Leads the Market Due to Optimal Efficacy & Safety, and Enhanced Patient Convenience

By dosage strength, the 2 mg segment is expected to contribute the highest share of the global Eylea market with a share of 45.5% in 2025. The 2 mg dosage of Eylea has emerged as the gold standard in the treatment of various retinal disorders, including Neovascular AMD, Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion (RVO). The segment's dominance can be attributed to several factors, starting with the optimal balance between efficacy and safety offered by the 2 mg dosage. Clinical trials have consistently shown that the 2 mg dose provides significant improvements in visual acuity and reduces the risk of vision loss, making it the preferred choice among healthcare professionals.

Moreover, the convenience associated with the 2 mg dosage has been a major driving force behind its market leadership. The less frequent injection schedule, typically every 4 to 8 weeks, reduces the treatment burden on patients and improves adherence to therapy. This not only enhances patient comfort but also reduces the overall healthcare costs associated with frequent clinic visits and injections.

Eylea Market Insights, By Packaging - Pre-filled Syringes Dominate the Market Due to Reduction in Medication Errors and Contamination, and Convenience

Based on packaging, the pre-filled syringe segment is expected to contribute the highest share of the global Eylea market with a share of 53.4% in 2025. The dominance of pre-filled syringes can be attributed to several key advantages that they offer over traditional vials. Firstly, pre-filled syringes significantly reduce the risk of medication errors and contamination during the preparation and administration of Eylea. The single-dose, ready-to-use format eliminates the need for complex dilution and transfer steps, minimizing the chances of dosing errors and ensuring accurate and consistent drug delivery.

Secondly, the ease of use and convenience associated with pre-filled syringes have been major driving factors for their market leadership. Healthcare professionals, particularly those in high-volume settings, appreciate the time-saving benefits of pre-filled syringes. The streamlined injection process allows for faster patient turnaround times and improved workflow efficiency, ultimately leading to better patient care and satisfaction.

Reimbursement Scenario

• EYLEA4U coverage and reimbursement support is a comprehensive program provided by Regeneron Pharmaceuticals, Inc., designed to help patients and healthcare providers navigate the complexities of insurance coverage and reimbursement for Eylea. The program offers assistance in verifying insurance benefits, understanding co-pays, and obtaining necessary approvals for Eylea treatment. EYLEA4U ensures that patients, even those facing challenges with their insurance coverage, can access the medication they need, with support tailored to help reduce the financial strain of securing treatment.
• Eylea patient assistance & financial cost support offers financial aid to eligible patients who are uninsured or underinsured. This initiative, also backed by Regeneron Pharmaceuticals, Inc., provides financial assistance to help cover the costs of Eylea, ensuring that financial barriers do not prevent access to essential care. Through these programs, Regeneron Pharmaceuticals works to ensure that all patients, regardless of their financial circumstances or insurance coverage, can receive the necessary treatment for conditions like neovascular (wet) age-related macular degeneration and diabetic macular edema (DME).

Regional Insights

To learn more about this report, Download Free Sample

North America Eylea Market Analysis and Trends

In North America, the dominance in the global Eylea market can be attributed to several factors with a share of 38.3% in 2025. The region boasts a well-established healthcare infrastructure, coupled with a high prevalence of age-related macular degeneration (AMD) and diabetic retinopathy, which are the primary indications for Eylea. The presence of key market players, such as Regeneron Pharmaceuticals, Inc., which develops and manufactures Eylea, further strengthens the region's position.

 Additionally, the presence of favorable reimbursement policies and a strong emphasis on research and development activities are contributing to the North America's dominance in the global Eylea market. For instance, in August 2023, the U.S. Food and Drug Administration (FDA) approved a higher dose of Regeneron Pharmaceuticals Eylea, a drug used for treating eye diseases like wet age-related macular degeneration. This approval allows for increased dosing intervals, offering patients fewer injections while maintaining treatment efficacy.

Asia Pacific Eylea Market Analysis and Trends

Asia Pacific exhibits the fastest growth in the global Eylea market with an estimated 24.2% market share in 2025. The region's rapid growth can be ascribed to several factors, such as the rising prevalence of AMD and diabetic retinopathy, increasing healthcare expenditure, and growing awareness about the availability of effective treatments like Eylea.

The expanding middle class and aging population in countries such as China and India are creating  a high demand for advanced ophthalmological treatments. The Asia Pacific Eylea market also benefits from the presence of local pharmaceutical companies that are actively involved in the distribution and promotion of Eylea in the region.

For Instance, According to research by Elsevier Ltd, In December 2022, A nationwide screening study conducted across 10 Indian states found that the prevalence of diabetic retinopathy (DR) was 12.5%, while vision-threatening diabetic retinopathy (VTDR) was 4.0%. The study included 42,146 participants, with 7,910 identified as having diabetes, and showed that individuals with known diabetes had a significantly higher prevalence of DR (15.5%) and VTDR (5.3%) compared to those with undiagnosed diabetes (8.0% and 2.4%, respectively).

Global Eylea Market Outlook for Key Countries

U.S. Eylea Market Trends

The U.S. market for Eylea is experiencing a decline, attributed to a combination of factors such as the market's maturity and the growing competition from biosimilars and alternative treatment options. Despite this decline, the large patient population, well-established healthcare system, and favorable reimbursement policies continue to support the treatment's use. Regeneron Pharmaceuticals, Inc., the developer and manufacturer of Eylea, has played a significant role in its past success. Additionally, while the country still has a strong network of ophthalmologists and retinal specialists prescribing Eylea for AMD and diabetic retinopathy, the market's downward trajectory is evident. The U.S. research and development ecosystem remains robust, but with the decreasing market size, further innovations are required to maintain the drug's relevance.

Japan Eylea Market Trends

While Japan's Eylea market remains significant, it has faced increasing challenges in recent years. Rapidly aging population and the increasing prevalence of AMD and diabetic retinopathy had supported growth, but the market is now experiencing a decline. Despite efforts from the Japanese government to improve access to innovative treatments and the presence of a well-established healthcare infrastructure, the downward market trend is becoming more pronounced, impacted by biosimilars and cost containment measures.

For instance, in April 2024, Santen Pharmaceutical Co., Ltd. and Bayer Yakuhin, Ltd., both headquartered in Osaka, Japan, jointly announced the launch of Eylea 8 mg (aflibercept 114.3 mg/mL) on April 17, 2024. This advanced ophthalmic VEGF inhibitor is approved for neovascular age-related macular degeneration (nAMD) and macular edema treatment (DME). Compared to the previous 2 mg version, Eylea 8 mg allows extended dosing intervals up to 16 weeks, significantly reducing injection frequency while maintaining safety and efficacy.

Germany Eylea Market Trends

Germany's Eylea market, while still significant, has been experiencing a decline in recent years. Despite the country's advanced healthcare system, high healthcare expenditure, and an aging population, the market faces increasing competition from biosimilars and alternative treatments. While ophthalmologists and retinal specialists continue to prescribe Eylea for AMD and diabetic retinopathy, the overall market is shrinking. Germany's established reimbursement policies and the presence of key players like Bayer AG, which holds the marketing rights for Eylea outside the U.S., have previously supported the product, but these factors are no longer sufficient to sustain growth in the face of a declining market.

For instance, in January 2024, the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). This approval follows positive results from the PULSAR and PHOTON clinical trials, showing that Eylea 8 mg offers significant durability with fewer injections, while maintaining comparable efficacy and safety to the original Eylea 2 mg.

China Eylea Market Trends

In China, the market for Eylea has experienced rapid growth in previous years, driven by the country's large population, increasing healthcare awareness, and rising disposable incomes. However, recent data suggests that this growth is plateauing, and the market is now on a decline. The Chinese government’s efforts to improve access to innovative treatments, combined with the increasing prevalence of AMD and diabetic retinopathy, initially drove demand. However, the market now faces significant challenges, including the presence of local alternatives and the shortage of trained ophthalmologists. Local pharmaceutical companies that once fueled Eylea's expansion now face increased competition, contributing to the overall market downturn.

Market Players, Key Development, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In April 2025, Regeneron Pharmaceuticals, Inc., a prominent U.S.-based biotechnology company, announced that the U.S. FDA had approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The approval is based on results from the PULSAR and PHOTON trials, where EYLEA HD showed vision outcomes comparable to the 2 mg version but with fewer injections.
• In January 2025, Bayer AG, a global life sciences company headquartered in Germany, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Eylea 8 mg (aflibercept) for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The approval follows strong clinical results from the PULSAR and PHOTON trials, which demonstrated that Eylea 8 mg offers comparable efficacy and safety to the 2 mg version, but with extended treatment intervals—reducing injection frequency for patients.

Top Strategies Followed by Global Eylea Market Players

• Established players in the global Eylea market are focusing on extensive research and development to innovate high-performance products. These companies invest heavily in R&D to stay ahead of the competition and offer cutting-edge solutions to their customers. For instance, leading companies in the market are developing advanced formulations and delivery systems to enhance the efficacy and safety of Eylea. Moreover, these players are also forming strategic partnerships with major industry players and original equipment manufacturers (OEMs) to solidify their market presence.
  • For instance, in April 2024, Santen Pharmaceutical Co., Ltd. and Bayer Yakuhin, Ltd., both headquartered in Osaka, Japan, jointly announced the launch of Eylea 8 mg (aflibercept 114.3 mg/mL) on April 17, 2024. This advanced ophthalmic VEGF inhibitor is approved for neovascular age-related macular degeneration (nAMD) and macular edema treatment (DME). Compared to the previous 2 mg version, Eylea 8 mg allows extended dosing intervals up to 16 weeks, significantly reducing injection frequency while maintaining safety and efficacy.

• Mid-level players in the global Eylea market are focusing on delivering cost-effective solutions to target price-sensitive consumers. These companies are optimizing their manufacturing processes and leveraging economies of scale to offer quality products at competitive prices. They are also engaging in collaborations with other industry players to boost their technology and production capabilities.

• Small-scale players in the global Eylea market are adopting niche specialization strategies to differentiate themselves from larger competitors. They are focusing on developing unique features or innovative products that cater to specific market segments. These players are also leveraging cutting-edge technologies, such as advanced analytics and automation, to streamline their operations and remain competitive in the market.

Market Report Scope

Eylea Market Report Coverage

Eylea Market Trends

To learn more about this report, Download Free Sample

Eylea Market Driver - Increasing Prevalence of Ocular Diseases

The global Eylea market, while influenced by the rising prevalence of ocular diseases and an aging population, is experiencing a decline. Conditions like age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are increasing, but the market is facing significant challenges. The emergence of biosimilars, pricing pressures, and alternative treatments are limiting Eylea's growth, despite the ongoing demand for effective therapies. As a result, the market is expected to shrink, even with the growing need for treatments driven by rising diabetes-related eye conditions.

For instance, according to data by the College of Optometrists, in January 2025, a new U.K.’s Eye Care Data Hub, launched by the College of Optometrists in collaboration with U.K. eye care organizations, predicts a significant rise in the prevalence of eye diseases over the next 10 years. The tool forecasts a 24.4% increase in late-stage age-related macular degeneration (AMD), a 15.9% rise in primary open-angle glaucoma, and a 16.7% growth in vision-impairing cataracts. It also models the future eye care workforce, projecting a 38.2% increase in optometrists, a 50% rise in orthoptists, and a 71.2% jump in consultant ophthalmologists, while some eye care roles like dispensing opticians and nurses are expected to decline.

Eylea Market Opportunity - Development of Combination Therapies

The global Eylea market presents a promising opportunity through the development of combination therapies. Combination therapies involve the use of Eylea in conjunction with other therapeutic agents or treatments to enhance its efficacy and address complex eye disorders. By combining Eylea with complementary drugs or therapies, healthcare providers can potentially achieve better patient outcomes, faster disease control, and improved long-term treatment success. The development of combination therapies opens up new avenues for the Eylea manufacturers to expand their market reach and target specific patient populations with unmet medical needs.

Collaborations with other pharmaceutical companies or research institutions can facilitate the identification of suitable combination partners and accelerate the development process. Additionally, the successful development and commercialization of combination therapies can differentiate Eylea from its competitors, providing a unique selling proposition and strengthening its market position. As the understanding of eye disorders advances and personalized medicine gains traction, the demand for tailored combination therapies is likely to grow, presenting a significant opportunity for the Eylea manufacturer to meet the evolving needs of patients and healthcare providers in the global Eylea market.

Analyst Opinion (Expert Opinion) 

• The global Eylea market is experiencing a stagnation & seeing limited growth, despite advancements in treatment efficacy and regulatory support. Technological innovations, such as long-acting formulations like Eylea HD, are providing extended treatment intervals, which improve patient compliance and convenience. While the demand for effective treatments for wet age-related macular degeneration (AMD) and diabetic macular edema (DME) persists, challenges such as the high cost of treatments, competition from biosimilars, and the need for frequent injections continue to limit market growth.
• Recent conferences such as the American Academy of Ophthalmology (AAO) Annual Meeting and the European Society of Retina Specialists (EURETINA) Congress have played pivotal roles in advancing knowledge and promoting new technologies in the field of ophthalmology, including Eylea. These events have provided a platform for sharing clinical data, exploring innovative treatments, and discussing regulatory trends. Additionally, initiatives like the SPECS 2030 program by the WHO aim to increase access to eye care globally, potentially expanding the market for treatments like Eylea. Such global efforts to improve eye care are expected to drive future market growth and broaden patient access to effective treatments.

Market Segmentation

•  Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Retinopathy of Prematurity (ROP)
•  Dosage Strength Insights (Revenue, USD Mn, 2020 - 2032)
  • 2 mg
  • 4 mg
  • 8 Mg
• Packaging Insights (Revenue, USD Mn, 2020 - 2032)
  • Pre-filled Syringe
  • Vial
•  Patient Age Group Insights (Revenue, USD Mn, 2020 - 2032)
  • Pediatric
  • Adult
  • Geriatric
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Regeneron Pharmaceuticals
  • Bayer AG

Sources

Primary Research Interviews

• Ophthalmologists and Retinal Specialists
• Clinical trial coordinators and research staff
• Key opinion leaders (KOLs) in ophthalmology and retinal diseases
• Healthcare providers and hospital administrators involved in retinal disease treatment
• Biotech and pharmaceutical company executives
• Regulatory bodies involved in ophthalmic treatments

Databases

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• National Institutes of Health (NIH)

    Global Health Data Exchange (GHDx) Magazines

• Ophthalmology Times
• Retina Today
• Medical Device and Diagnostic Industry (MD+DI)
• EyeNet Magazine
• The Pharmaceutical Journal

Journals

• Ophthalmology Journal
• Retina Journal
• American Journal of Ophthalmology
• Journal of Ocular Pharmacology and Therapeutics
• The Lancet Ophthalmology

Newspapers

• The New York Times
• The Wall Street Journal
• Financial Times
• The Guardian
• Reuters Health

Associations

• American Academy of Ophthalmology (AAO)
• European Society of Retina Specialists (EURETINA)
• International Retina Research Foundation (IRRF)
• World Health Organization’s Vision 2020
• International Agency for the Prevention of Blindness (IAPB)

Public Domain Sources

• U.S. National Library of Medicine
• OECD Health Statistics

  Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years